[Southern + November 11th] According to Russian media reports, the Russian Sovereign Wealth Fund (RDIF) said on the 11th that the results of the mid-term test showed that the Russian satellite V (Sputnik V) vaccine is effective in protecting people from the new coronavirus infection. The sex is 92%. Currently, Moscow is trying to catch up with Western drugmakers.
Russian satellite V vaccine
According to reports, this is the second human experimental result announced in the global new crown vaccine competition. A vaccine race is currently underway around the world to try to stop the global new crown pneumonia pandemic, which has caused more than 1.2 million deaths and disrupted the world economy. The Russian Direct Investment Fund (RDIF) said that the results of the mid-term experiment announced this time are based on the data of the first batch of 16,000 participants in the vaccination trial. The vaccine developed by the Russian National Research Center for Epidemiology and Microbiology is undergoing Phase III trials in 29 clinics in Moscow, involving a total of 40,000 volunteers, of which a quarter will receive a placebo injection.
The Russian Direct Investment Fund (RDIF) stated that people who received the satellite V vaccine were 92% less likely to contract new coronavirus pneumonia than those who received a placebo. This is much higher than the 50% effectiveness threshold of the new coronary pneumonia vaccine set by the US Food and Drug Administration (FDA). Kirill Dmitriev, head of Russia’s sovereign wealth fund, said: “According to the data, we are developing a very effective vaccine.” Foreign media said that previously, vaccine research and development company Pfizer Inc. .) and the biotechnology company (BioNTech) announced the effect of the vaccine on Monday, saying that their vaccine also has more than 90% of the effect, which may accelerate the speed at which Russia announces its vaccine effectiveness.
According to reports, Pfizer and BioNTech vaccines in the United States use mRNA technology to trigger an immune response without the use of pathogens (such as real new coronaviruses). The satellite V vaccine uses two adenoviruses as carriers, human adenovirus Ad5 and Ad26, and is injected twice to trigger the human immune response within 21 days. In addition to the US Pfizer and Russian satellite vaccines, there are 8 new coronavirus vaccines worldwide that have entered phase 3 clinical trials, of which 4 are from China, 2 from the US, one from Germany, and one from the UK.
proofreading Liu Jun
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-